Helping you make decisions about antipsychotic medicines
Part of Mental health clinical trials.
This study tests a “shared decision-making” approach to help you and your clinic choose how to use antipsychotic medicines. It may help you feel more involved in decisions if you’re currently taking an antipsychotic, recently stopped, or are thinking about stopping.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 30 years old
- Have had a diagnosis in the schizophrenia/spectrum or related psychotic conditions (nonaffective psychosis)
- Have experience with antipsychotic medicines (currently taking, stopped, or considering stopping)
- Receive early psychosis clinic care through OnTrackNY for about 3 months
- Be willing to do research interviews after each antipsychotic medicine visit during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses brain scans and real-life surveys to understand how people with or without schizophrenia make decisions. It may help researchers learn how the brain works differently in schizophrenia.
This trial tests a combination of an NMDA-targeting medicine and an anti-inflammatory treatment for people with schizophrenia that has not responded well to several standard treatments, including clozapine. If you qualify, the goal is to see whether this combination improves symptoms more than usual care.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
This study tests whether a new medication called aticaprant is safe and well-tolerated when added to your current antipsychotic medication for schizophrenia. The goal is to see if it could help improve symptoms without causing serious side effects.
This trial tests whether combining an NMDA “signal-supporting” treatment with an anti-inflammatory medicine can reduce symptoms in people with schizophrenia who don’t respond well to usual antipsychotic drugs. If you’ve tried at least two antipsychotics and you’re still symptomatic, this study may be worth screening for.
This trial tests a program called iTEST that helps people with schizophrenia or schizoaffective disorder improve how accurately they understand their own thoughts. The program combines device use with feedback from a clinician or loved one to support better self-awareness.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.